273 related articles for article (PubMed ID: 18801766)
1. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Br J Ophthalmol; 2009 Feb; 93(2):150-4. PubMed ID: 18801766
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
[TBL] [Abstract][Full Text] [Related]
4. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Ares S; Lopez-Lopez F; Rodriguez M; Fernandez M
Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
6. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
[TBL] [Abstract][Full Text] [Related]
9. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
12. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F
Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
14. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
15. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
17. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
[TBL] [Abstract][Full Text] [Related]
20. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
